- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05215015
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia
January 18, 2022 updated by: Wuxi People's Hospital
Clinical Study of Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells Targeting CD33 and CLL1 in Patients With Acute Myeloid Leukemia
This is an open-label, nonrandomized, investigator-initiated clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of anti-CD33/CLL1 CAR-NK cell injection in patients with acute myeloid leukemia (AML), and to determine PK parameters, maximum tolerated dose (MTD), and phase II recommended dose (RP2D) for subjects receiving CAR-NK cell injection.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The treatment cycle in this study is 28 days.
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle.
Subjects will be treated continuously until the criteria for termination of treatment are met.
In this study, the dose escalation design is adopted.
The first administration dose in the first cycle is 2.0×10^9 cells.
If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peihua Lu, MD
- Phone Number: +8613583991399
- Email: lyzlyylxm@163.com
Study Contact Backup
- Name: Xin Zhou, MD
- Phone Number: +8613358111962
- Email: 13625653@qq.com
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China
- Recruiting
- Wuxi People's Hospital
-
Contact:
- Peihua Lu, MD
- Phone Number: +8613583991399
- Email: lyzlyylxm@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects should voluntarily participate in this clinical study, are fully aware of the study, have signed the Informed Consent Forms, and are willing to follow and able to complete all trial procedures.
- Subjects who are more than 18 years old (including 18 years old), and less than 75 years old (including 75 years old);
Subjects who are diagnosed as AML according to the World Health Organization (WHO) 2016 diagnosis criteria, and meet any of the following:
- Relapsed acute myeloid leukemia: after complete response (CR), there are leukemia cells in peripheral blood or blast cells in bone marrow >5% (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration.
- Refractory acute myeloid leukemia: treatment-naive subjects who have no response to the standard of care for 2 courses of treatment; subjects who are relapsed within 12 months with consolidated intensive treatment after CR; subjects who are relapsed after 12 months but have no response to the conventional chemotherapy; subjects who are relapsed twice or more; subjects who have persistent extramedullary leukemia.
- Subjects who are positive in CD33 or CLL1 test (according to the results of the central laboratory);
- Subjects are allowed to have received ≤1 autologous HSCT;
- Subjects whose performance status scores of the Eastern Cooperative Oncology Organization (ECOG) are≤2;
- Subjects with the expected survival phase>3 months;
Organ function should meet the following criteria:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), unless these are caused by leukemia cell infiltration as determined by the investigator;
- Total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN);
- Glomerular filtration rate (GFR)>50 mL/min;
- Left ventricular ejection fraction (LVEF)≥50%, no clinically significant pericardial effusion confirmed by echocardiography;
- Blood oxygen saturation under indoor ventilation in the screening phase>92%;
- Female subjects of childbearing age must be negative in the pregnancy test results in the screening phase;
- Male and female subjects of childbearing age must agree to take effective birth controls after signing the informed consent forms, during the study, and within 6 months after the last administration.
Exclusion Criteria:
- Subjects who are known to have acute promyelocytic leukemia;
- Subjects who suffer from or are suspected of suffering from central nervous system leukemia, or central nervous system involvement;
- Subjects who have received allogeneic HSCT;
- Subjects who have prior II-IV (Glucksberg criteria) acute graft versus-host disease (GvHD) or extensive chronic GvHD;
- Subjects who have received chimeric antigen receptor cell therapy or other cell therapy;
- Subjects who have received anti-tumor therapy in the early stage but are not recovered in the toxicity (according to NCI-CTCAE 5.0, the toxicity has not recovered to ≤ Grade 1, except for fatigue, anorexia, and alopecia);
- Subjects who have had other malignant tumors within 5 years before inclusion, except for any type of carcinoma in situ that has been cured in the past and cured skin basal cell carcinoma or skin squamous cell carcinoma;
Subjects whose cardiac function and disease meet one of the following conditions within 6 months before the first administration:
- Any risk factors that increase QTcF (Fridericia formula) interval prolongation, such as uncorrectable hypokalemia, hereditary long QT syndrome, and use of drugs that prolong the QTcF interval;
- New York Heart Association (NYHA) classification ≥Grade 3;
- QTcF interval prolongation (male>450 milliseconds; female>470 milliseconds);
- Unstable angina pectoris, and myocardial infarction;
- Subjects who have a history of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that require systemic immunosuppressive/systemic disease modulating drugs within 2 years before the first administration;
- Subjects who have active systemic fungal, bacterial or viral infections that are uncontrolled or are required to be treated by intravenous administration;
- Subjects with human immunodeficiency virus (HIV) antibody positive;
- Subjects with HBsAg (-) and HBcAb (-). If subjects have HBsAg (+) and/or HBcAb (+), then subjects with HBV-DNA below the local lower limit of quantification can be included;
- Subjects with hepatitis C virus antibody (-). If subjects have hepatitis C virus antibody (+), then subjects with HCV-RNA (-) can be included;
- Female subjects who are breastfeeding and unwilling to stop breastfeeding;
- Subjects who have received major surgery (for the definition of major surgery, refer to the Level 3 and 4 surgeries specified in the Administrative Measures for the Clinical Application of Medical Technology) within 28 days before the first administration.
- Subjects who have received a solid organ transplant;
- Subjects who have a history of alcohol, drug use or drug abuse;
- Subjects who are known to be allergic to the study drug and/or main components and/or any excipients of the study drug;
- Subjects who have other severe, acute, or chronic diseases or laboratory abnormalities that may increase the risk of participating in the study and receiving the study drug, or may interfere with the interpretation of study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-CD33/CLL1 CAR-NK Cells
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days).
The first administration dose in the first cycle is 2.0×10^9 cells.
If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
|
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days).
The first administration dose in the first cycle is 2.0×10^9 cells.
If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limiting toxicity (DLT)
Time Frame: 28 days after initial infusion
|
To evaluate the safety and tolerability of Anti-CD33/CLL1 CAR-NK cells
|
28 days after initial infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to 1 year after infusion
|
To evaluate the effectivity of anti-CD33/CLL1 CAR-NK cells
|
Up to 1 year after infusion
|
Minimal residual disease (MRD)
Time Frame: Up to 1 year after infusion
|
To evaluate the effectivity of anti-CD33/CLL1 CAR-NK cells
|
Up to 1 year after infusion
|
Objective response rate (ORR)
Time Frame: Up to 1 year after infusion
|
To evaluate the effectivity of anti-CD33/CLL1 CAR-NK cells
|
Up to 1 year after infusion
|
Duration of overall response (DOR)
Time Frame: Up to 1 year after infusion
|
To evaluate the effectivity of anti-CD33/CLL1 CAR-NK cells
|
Up to 1 year after infusion
|
Plasma concentration of CAR-NK cells
Time Frame: One month after the last infusion
|
Blood samples will be collected at specified time points to detect the number of CAR-NK cells in peripheral blood and to evaluate the PK parameters
|
One month after the last infusion
|
Cytokine release
Time Frame: One month after the last infusion
|
Blood samples will be collected at specified time points to detect the cytokine (IL-6, TNF-α, IL-1ra, IL-10, IL-2, etc.) concentration (pg/mL)
|
One month after the last infusion
|
Adverse Events (AEs)
Time Frame: From day 1 to day 90 after the last infusion
|
The incidence and severity of adverse events assessed according to Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, and the correlation between adverse events and CAR-NK cells
|
From day 1 to day 90 after the last infusion
|
Percentage of subjects receiving hematopoietic stem cell transplantation (HSCT)
Time Frame: Up to 1 year after infusion
|
To explore HSCT in subjects receiving CAR-NK cell therapy.
|
Up to 1 year after infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2020
Primary Completion (Anticipated)
November 30, 2022
Study Completion (Anticipated)
November 30, 2022
Study Registration Dates
First Submitted
January 18, 2022
First Submitted That Met QC Criteria
January 18, 2022
First Posted (Actual)
January 31, 2022
Study Record Updates
Last Update Posted (Actual)
January 31, 2022
Last Update Submitted That Met QC Criteria
January 18, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IBR733-T01
- WX-IBR-7 (Other Identifier: Wuxi People's Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Anti-CD33/CLL1 CAR-NK Cells
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownAcute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Myeloid Leukemia With Maturation | Acute Myeloid Leukemia Without Maturation | ANLLChina
-
Guangzhou Bio-gene Technology Co., LtdWithdrawnAcute Myeloid LeukemiaChina
-
Zhejiang UniversityNot yet recruiting
-
iCell Gene TherapeuticsThe General Hospital of Western Theater Command; Peking University Shenzhen... and other collaboratorsRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative NeoplasmChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
920th Hospital of Joint Logistics Support Force...RecruitingAcute Myeloid LeukemiaChina
-
Southwest Hospital, ChinaUnknown
-
Zhejiang UniversityYake Biotechnology Ltd.Recruiting
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Fujian Medical UniversityUnknown